BMS’ Opdivo (nivolumab) Receives NICE Recommendation as 1L Treatment for Rare Gastroesophageal Cancers
Shots:
- The NICE has issued a final draft guidance recommending BMS’ Opdivo + CT as a treatment option for untreated HER2-, advanced or metastatic gastric, GEJ, or oesophageal adenocarcinoma in patients whose tumors express PD-L1 with a CPS of ≥5
- The decision was based on the P-III (Checkmate-649) trial evaluating Opdivo (360mg, q3w or 240mg, q2w) + CT vs CT alone in patients which showed an improvement in OS & PFS, m-OS (14.4mos. vs 11.1mos.), m-PFS (8.31mos. vs 6.05mos.), significant OS benefit was also observed in PD-L1+ patients with CPS ≥1 & in the all-randomized population
- The safety profile was consistent with the known safety profiles of the individual treatments & no new safety signals were reported
Ref: Nice | Image: BMS
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
